These webinars will provide insight and advice on how electronic image transfer can improve the speed and reduce the costs of collecting DXA images in clinical trials and provide useful information for planning trials using body composition
West Lebanon, NH (PRWEB) February 9, 2009
M2S Inc., a global provider of image management services for biopharmaceutical and medical device clinical trials, announced today that the company will be holding two free webinars to discuss how state-of-the-art image management can enhance DXA (Dual Energy X-Ray Absorptiometry) quality assurance services for bone mineral density trials and issues to consider in trials using body composition measurements with DXA.
On February 3, 2009 (1:00pm EST), an expert from M2S' DXA Division will present the benefits of electronic image transfer, real-time web-based tracking and processing of DXA bone mineral density images and discuss the potential time and cost savings. The second webinar, to be held February 10 (1:00pm EST), will provide useful information on potential challenges and issues in clinical trials using body composition measurements such as patient positioning, use of phantoms, analysis and outcomes decisions.
DXA (Dual- Energy X-Ray Absorptiometry) is a low-dose (1/10th of traditional x-ray) imaging modality that measures bone mineral density and body mass composition. It is increasingly utilized in clinical trials to assess the safety and effectiveness of drugs under development for osteoporosis, HIV, obesity, oncology, as well as hormonal therapies and pediatric indications.
"These webinars will provide insight and advice on how electronic image transfer can improve the speed and reduce the costs of collecting DXA images in clinical trials and provide useful information for planning trials using body composition," said Reta Rupich, Vice President, M2S DXA division.
To sign up for one or both free webinars, go to our DXA Webinar Sign up Page
About M2S, Inc.:
M2S provides image and data management services for clinical trials sponsors in the biopharmaceutical and medical device industries, patient registry databases and is a recognized leader in 3-D endovascular treatment planning. On December 31, 2008 M2S acquired DXA Resource Group (DRG), a clinical trials service company focused on providing customer-centric, cost-effective quality assurance as well as data and project management for clinical trials involving DXA measurements. For the past 10 years, M2S has managed, under protocol, millions of images from around the globe in various therapeutic areas and in all DICOM modalities. For more information, visit http://www.m2s.com or http://www.dxaresourcegroup.com.